Choline alfoscerate in the correction of cognitive impairment
Open Access
- 17 December 2023
- journal article
- research article
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 15 (6) , 128-134
Abstract
In preclinical and clinical studies, choline alfoscerate (CA) has proven to be highly effective in the correction of cognitive impairment (CI). The clinical effect of CA is seen in the improvement of mental activity, concentration, ability to remember and recall information, cognitive and behavioural responses, elimination of emotional instability and apathy. Experimental studies have shown the effectiveness of CA in preventing atrophic changes in the cerebral cortex. Based on several studies conducted on the use of CA in the treatment of CI, it can be concluded that oral administration of CA at a dose of 600 mg/day can be recommended both as monotherapy and as part of complex therapy in patients with cerebrovascular diseases such as chronic cerebral ischemia. As part of complex therapy for CI in Alzheimer's disease, a combination of CA at a dose of 1200 mg/day with donepezil at a dose of 10 mg/day may be recommended. Several studies have demonstrated the efficacy of CA in the treatment of post-COVID and post-traumatic CI. The efficacy of CA administration in the treatment of CI (including vascular dementia) following ischemic stroke and transient ischemic attacks has been demonstrated. When CA is taken, there is also a reduction in anxiety and depressive disorders, asthenia, the severity of pain symptoms and changes in coordination. The duration of therapy should be 60 to 90 days, depending on the severity of CI, followed by an observation phase of up to 2 years. For successful treatment with CA, it is necessary to carry out repeated courses of CI treatment. Today, a new drug Cerpechol (600 mg/7 ml) has appeared on the Russian market, which has all the effects of CA. The convenience of the new form (oral solution) makes it possible to use it in patients with swallowing disorders.Keywords
This publication has 19 references indexed in Scilit:
- Fatigue and cognitive impairment in post-COVID syndrome: possible treatment approachesNeurology, Neuropsychiatry, Psychosomatics, 2021
- Efficacy and Safety of the Association of Nimodipine and Choline Alphoscerate in the Treatment of Cognitive Impairment in Patients with Cerebral Small Vessel Disease. The CONIVaD TrialDrugs & Aging, 2021
- Cerebral small vessel disease and vascular cognitive impairment: from diagnosis to managementCurrent Opinion in Neurology, 2021
- Efficacy and Safety of Citicoline to Prevent Cognitive Deficiency Progression in First-Degree Relatives of Patients with Alzheimer’s Disease: Prospective StudyPsychiatry (Moscow) (Psikhiatriya), 2020
- Volume Analysis of Brain Cognitive Areas in Alzheimer’s Disease: Interim 3-Year Results from the ASCOMALVA TrialJournal of Alzheimer’s Disease, 2020
- Correction of post-stroke cognitive and motor disordersRussian Medical Inquiry, 2020
- Canadian Consensus Conference on Diagnosis and Treatment of Dementia (CCCDTD)5: Guidelines for management of vascular cognitive impairmentAlzheimer's & Dementia: Translational Research & Clinical Interventions, 2020
- Transient ischemic attacks: their importance in the progression of cerebrovascular diseases and topical issues of medical rehabilitationMeditsinskiy sovet = Medical Council, 2019
- Association of nimodipine and choline alphoscerate in the treatment of cognitive impairment in patients with cerebral small vessel disease: study protocol for a randomized placebo-controlled trial—the CONIVaD trialAging Clinical and Experimental Research, 2019
- The ASCOMALVA (Association between the Cholinesterase Inhibitor Donepezil and the Cholinergic Precursor Choline Alphoscerate in Alzheimer's Disease) Trial: Interim Results after Two Years of TreatmentJournal of Alzheimer’s Disease, 2014